Figure 4. Different responses to immunotherapy of patients belonging to the established molecular subclasses. (A) Similarity between patients of different subclasses and patients with melanoma who received ICI treatment were compared using the submap algorithm. Patients in the immune-activated subclass had higher mRNA expression profile similarity with patients that responded to anti-PD-1 treatment. (B) Distribution of the clinical response to ICI treatment in the three immunophenotypes was determined using the TIDE analysis. Patients in the immune-activated subclass had a higher predicted response rate than the other two groups.